PLP1 and Pelizeaus-Merzbacher spectrum disorder: Stem cell therapy for PMD has undergone a clinical safety trial in four patients with connatal forms due to point mutations in the PLP1 gene, in whom myelin is absent by MRI (Gupta et al., 2012, 2019).